Fox Run Management L.L.C. Makes New $863,000 Investment in Vera Therapeutics, Inc. $VERA

Fox Run Management L.L.C. bought a new position in Vera Therapeutics, Inc. (NASDAQ:VERA) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 17,033 shares of the company’s stock, valued at approximately $863,000.

Other institutional investors also recently modified their holdings of the company. Hudson Bay Capital Management LP raised its stake in shares of Vera Therapeutics by 47.4% in the third quarter. Hudson Bay Capital Management LP now owns 440,591 shares of the company’s stock worth $12,804,000 after acquiring an additional 141,615 shares during the last quarter. UBS Group AG raised its stake in shares of Vera Therapeutics by 27.9% in the fourth quarter. UBS Group AG now owns 207,289 shares of the company’s stock worth $10,497,000 after acquiring an additional 45,214 shares during the last quarter. Schroder Investment Management Group raised its stake in shares of Vera Therapeutics by 82.4% in the third quarter. Schroder Investment Management Group now owns 679,992 shares of the company’s stock worth $19,652,000 after acquiring an additional 307,243 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Vera Therapeutics by 6.3% during the third quarter. Vanguard Group Inc. now owns 3,190,653 shares of the company’s stock worth $92,720,000 after buying an additional 189,545 shares during the last quarter. Finally, Braidwell LP bought a new stake in shares of Vera Therapeutics during the third quarter worth approximately $13,738,000. 99.21% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on VERA shares. HC Wainwright boosted their price target on shares of Vera Therapeutics from $90.00 to $110.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Jefferies Financial Group reissued a “buy” rating and set a $60.00 price target on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Evercore set a $91.00 price target on shares of Vera Therapeutics in a research note on Friday, May 15th. TD Cowen reissued a “buy” rating on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Vera Therapeutics in a research note on Monday, April 20th. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $78.00.

Insider Buying and Selling at Vera Therapeutics

In other news, CEO Marshall Fordyce sold 22,951 shares of the company’s stock in a transaction that occurred on Tuesday, April 14th. The shares were sold at an average price of $44.05, for a total value of $1,010,991.55. Following the completion of the transaction, the chief executive officer owned 235,244 shares in the company, valued at $10,362,498.20. This represents a 8.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 15.90% of the stock is owned by company insiders.

Vera Therapeutics Stock Down 0.6%

Vera Therapeutics stock opened at $31.62 on Thursday. The stock has a market capitalization of $2.27 billion, a PE ratio of -5.71 and a beta of 0.93. Vera Therapeutics, Inc. has a twelve month low of $19.07 and a twelve month high of $56.05. The company has a quick ratio of 13.64, a current ratio of 13.64 and a debt-to-equity ratio of 0.15. The company has a 50 day moving average of $37.27 and a 200-day moving average of $41.40.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same quarter in the prior year, the business posted ($0.81) EPS. On average, equities research analysts anticipate that Vera Therapeutics, Inc. will post -6.23 EPS for the current fiscal year.

Vera Therapeutics Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.